Skip to main content
    S

    Sutro Biopharma (STRO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $9.32
    -0.50 (-5.09%)

    Market Cap: $163.03M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Sutro Biopharma (STRO) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Sutro Biopharma (STRO) to earn -$7.48 per share in the fiscal year ending Dec 31, 2026, on revenue of $52.63M. Of 14 analysts, 13 rate the stock Buy or Strong Buy, 0 Hold and 1 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 14 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 93% of the ratings.

    RatingAnalystsShare
    Strong Buy321.4%
    Buy1071.4%
    Hold00.0%
    Sell00.0%
    Strong Sell17.1%
    Consensus
    Buy
    Total analysts
    14

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates fall 40.7%.

    Fiscal year ending Dec 31, 2026
    -$7.48
    EPS consensus, revenue $52.63M
    Fiscal year ending Dec 31, 2027
    -$6.11
    EPS consensus, revenue $31.23M
    Next report
    Mar 22, 2027
    Estimated

    EPS range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$7.48-$8.57 to -$6.392$52.63M$29.36M to $124.40M12
    Dec 31, 2027-$6.11-$9.32 to -$4.313$31.23MN/A12

    Quarterly Estimates

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$1.72-$2.70 to -$0.9516$11.62M$2.45M to $21.96M14

    Estimate Revisions

    Across the 2 periods below, the last 30 days brought 2 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202610
    Fiscal year ending Dec 31, 202710

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$8.47.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$7.48-$7.77-$7.77-$7.77-$8.47N/A
    Fiscal year ending Dec 31, 2027-$6.11-$6.21-$6.21-$6.21-$6.39N/A

    Frequently Asked Questions About STRO

    What is the STRO stock forecast?

    Consensus analyst estimates put Sutro Biopharma's EPS at -$7.48 for the fiscal year ending Dec 31, 2026, on revenue of $52.63M. The consensus rating from 14 analysts is Buy.

    How do analysts rate STRO stock?

    Of 14 analysts covering Sutro Biopharma, 3 rate it Strong Buy, 10 Buy, 0 Hold, 0 Sell and 1 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from STRO next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$7.48, with estimates from -$8.57 to -$6.39 from 2 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$6.11, with estimates from -$9.32 to -$4.31 from 3 analysts.

    What revenue do analysts expect from Sutro Biopharma next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $52.63M, with estimates from $29.36M to $124.40M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $31.23M.

    How many analysts cover STRO?

    14 analysts rate Sutro Biopharma stock, and 2 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.